Members of the government advisory panel NTAGI on Thursday agreed on reducing the gap between the second and precaution doses of COVID-19 vaccines from the current nine to six months, official sources said.
A recommendation for it will be made to the Health Ministry soon, they said.
The NTAGI's Standing Technical Sub-Committee (STSC), which met on Thursday, also reviewed the findings of a study by the Christian Medical College (CMC) in Vellore on the feasibility of allowing as precaution dose a Covid vaccine different from the one used for primary vaccination.
The panel members found a lack of uniformity in results upon mixing of jabs for booster shots and stated that no recommendation for it can be made as of now. The CMC study was on Covishield and Covaxin.
The threat of monkeypox and the requirement of vaccination were also discussed in the meeting, the sources said.
"However, the members were of the view that a strong surveillance is what is required as of now. No case of monkeypox has been detected in the country till now," one of the sources told PTI.
The panel also reviewed data on Covaxin and Corbevax vaccines for the 6-12 age group.
"The members opined that data of Covid burden and mortality among children is not robust enough to take any decision to begin vaccination of those below 12 years," the source stated.
India's drug regulator in April this year had granted emergency use authorisation for Biological E's COVID-19 vaccine Corbevax for those aged five to 12 years and Bharat Biotech's Covaxin for children in the age group of six to 12 years.
The STSC members were learnt to have also agreed on administration of an additional third dose for renal transplant patients before the precaution dose.
"In the meeting today, members also agreed on reducing the gap between the second and the precaution doses of COVID-19 vaccines from the current nine months to six months," the source told PTI.
Currently, all those above the age of 18 who have completed nine months after the administration of the second dose are eligible for the precaution dose.
The Union government last month allowed citizens and students travelling overseas to get the shot before the stipulated nine-month waiting period as required by the guidelines of the destination country.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app